Form 8-K/A · Amended current report
Synopsys 8-K/A, filed Aug 26, 2026
- Filed
- CIK
- 0000883241
- Accession no.
- 0001193125-26-368858
Summary
Synopsys's board approved updated estimates for its previously disclosed restructuring plan, raising expected pre-tax charges to between $425 million and $500 million, consisting primarily of severance and other one-time termination benefits plus costs such as certain site closures under its global site strategy. The company said the size, components, and timing of the charges could differ materially.
Key points
- Synopsys's board approved the updated restructuring estimates on August 21, 2026.
- The pre-tax charges are expected to range from $425 million to $500 million and be recognized in GAAP results.
- The costs consist primarily of severance and other one-time termination benefits, along with site closures tied to a global site strategy.
- Synopsys said implementation across jurisdictions and the timing of costs could cause actual results to differ from the estimates.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.05Costs Associated with Exit or Disposal Activities
From the filing
Item 2.05 Costs Associated with Exit or Disposal Activities. On August 21, 2026, the Board approved updated estimates related to the Restructuring Plan that were previously disclosed in the Original 8-K to reflect additional restructuring costs. Synopsys now estimates that it will recognize pre-tax charges to its GAAP financial results ranging from $425 million to $500 million, consisting primarily of severance and other one-time termination benefits, and other costs such as certain site closures as part of its global site strategy. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.